Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Videos|July 27, 2015
The Lessons of High Cost Specialty Drug Product Launches
Author(s)Davy James, Managing Editor
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.
Advertisement
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5